Compare SYSCO Corporation (SYY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? SYSCO Corporation trades at $81.58 (market cap $38.25B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: SYSCO Corporation pays a 2.76% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, SYSCO Corporation nearer its low. Which is the better fit depends on your goals.
| SYY | XBI | |
|---|---|---|
Market Cap | $38.25B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $91.16 | $169.55 |
52-Week Low | $69.30 | $93.43 |
Enterprise Value | $51.43B | — |
Dividend Yield | 2.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sysco Corporation (SYY) trades at $79.84, down 0.26% with a bullish technical signal despite mixed moving averages. The company reported $81.37B in revenue for 2025 with a 2.08% net margin and maintains strong analyst support with 60% buy ratings. Recent news highlights AI efficiency initiatives and reaffirmed 2027 guidance, while the pending Jetro Restaurant Depot acquisition presents both growth opportunities and integration risks.
Sysco offers stable fundamentals with consistent revenue growth and dividend aristocrat status, but faces execution risks from its major acquisition and margin pressures. The stock trades below the $88.25 consensus target, suggesting potential upside if AI efficiency gains materialize and integration proceeds smoothly.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
